The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.80
High: 0.80
Low: 0.80
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Micro Focus Rises On Outlook And Buyback

Mon, 05th Nov 2018 10:57

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Micro Focus International, up 3.0%. The software company said its annual revenue outlook is expected to come in at the better end of its previously guided range. On a constant currency basis, the company expects revenue to come in at the upper end of the guidance of a 6% to 9% decline for the financial year to October-end. Micro Focus highlighted that it traded in line with the board's expectations, as it saw revenue improvements in the second half. The company also announced its intention to recommence its share buyback programme, with any shares bought back to be held in treasury. From August 29 to October 24, Micro Focus bought back 9.9 million shares for USD171 million. The extended share buyback programme, when initiated, will cover an additional tranche of shares for up to USD400 million, inclusive of those already repurchased. ----------FTSE 100 - LOSERS----------Ashtead Group, down 3.0% at 1,905.00 pence. Barclays cut its price target on the equipment rental firm to 2,200p from 2,580p. ----------FTSE 250 - WINNERS----------Sirius Minerals, up 2.5%. The polyhalite mining company said it has awarded a contract to construct port handling facility for the Woodsmith polyhalite fertilizer mine located in north Yorkshire, England. The company's unit York Potash Processing and Ports has awarded a engineering, procurement and construction contract to civil engineering contractor McLaughlin & Harvey for developing port handling facility at Teesside, north east England. Under the contract, McLaughlin & Harvey will design and build the port storage facilities for 250,000 tonnes of product, ship loading equipment, ship outload infrastructure, and the final product screening facility. The port handling facility will store the company's polyhalite fertilizer after it has been transported from the Woodsmith mine and processed into the finished product at the Wilton Materials handling facility. ----------RPC Group, up 1.9%. The plastic product producer said it extended the deadline for talks over a potential takeover by private equity firms Apollo Global Management and Bain Capital to early December. In September, RPC confirmed that Apollo and Bain had approached it with a potential deal to buy the firm. The original deadline for Apollo and Bain to either announce a firm intention to make an offer or step away from a deal under UK takeover rules was October 8. Early in October, this was extended until 1700 GMT on Monday. RPC emphasised on Monday that "discussions remain ongoing" and consequently have agreed to extend the deadline further. With the fresh extension, the new deadline will be December 3 at 1700 GMT. The firm will provide a further announcement "when appropriate" and added there was "no certainty" an offer would be made. ----------FTSE 250 - LOSERS----------Hiscox, down 7.5%. The insurer said it enjoyed strong growth in the third quarter which saw total gross written premiums increase, but noted premium growth would slow towards the end of the year. For the nine months ended September, Hiscox reported a 14% year-on-year increase in total gross written premiums to USD3.04 billion from USD2.66 billion. Hiscox said a "benign" first half was followed by an "active" third quarter for both natural catastrophe and large claims, which has extended into October. In addition, the company said it expects growth to "moderate" over the remainder of 2018. Peel Hunt said Hiscox was unable to escape an "active" period of losses for the insurance industry, in part due to the growth of its portfolio over the past few years. In addition, Shore Capital said: "The challenging claims environment in the third quarter and muted guidance on growth for the rest of the year, however, are not positive, in our view."----------Babcock International, down 5.1%. RBC Capital downgraded the defence outsourcer to Sector Perform from Outperform. ----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 30%. The pharmaceutical company said MedImmune, a subsidiary of blue chip drugmaker AstraZeneca, confirmed its commitment to investigating non-lipid nanoparticle technologies for mRNA and pDNA delivery. MedImmune said it intends to continue to work with N4 Pharma to co-develop an optimised version of Nuvec under an appropriate collaboration agreement. The company's Nuvec system is intended to effectively deliver nucleic acids into cells leading to the production of antigens with potential activity as therapeutic entities or antigens for cancer vaccine. N4 Pharma partnered with MedImmune in February, following the conclusion of the Innovate UK feasibility grant. The grant was awarded to a collaborative project to explore the manufacture of a prototype nanomedicine using N4 Pharma's Nuvec system. ----------Symphony Environmental Technologies, up 10%. The 'smart' plastic maker said a report commissioned by the company by former deputy judge of the High Court in England Peter Susman said the case for oxo-biodegradable technology is "clear and compelling". Susman considered evidence from the EU Commission report from January 2018, the Loughborough Report for the UK government and the 2016 Eunomia Report. In his written opinion, Susman said oxo-biodegradable technology "does facilitate" the biodegradation of plastics in air or seawater by bacteria, fungi or algae. He believes this will "cause the plastic to cease to exist far sooner than ordinary plastics, without causing any toxicity". Susman also said the technology is compatible with composting and recycling. Chief Executive Michael Laurier said: "We are delighted that Peter Susman has found the scientific case for Symphony's d2w oxo-biodegradable technology to be proven."----------OTHER MAIN MARKET AND AIM - LOSERS----------Angus Energy, down 14% at 11.3p. The oil & gas production company said it intends to raise GBP2.0 million through a share placing for general working capital purposes and business development opportunities. Angus Energy plans to issue 22.2 million shares at a price of 9.0 pence each. The placing price represents a 23% discount to the 30-day volume weighted average share price. Angus Energy intends to use the proceeds to provide funds for general working capital purposes, principally in relation to the strategy at Brockham oil field located in Surrey, England. It also expects to use the funds to expand its portfolio of onshore development and appraisal projects.----------
More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.